Thus, cAMP/PKA-signaling regulated by PDE3B in adipose tissue and potential targeting of caspase-1 activation through NLRP3 inflammasome, may be a new therapeutic target for the development of anti-obesity and anti-inflammatory drugs. Here, NLRP3 is linked to obesity due to melanocortin 4 receptor deficiency.